ARTICLE | Clinical News
GS 504: Began a Phase II/III trial
January 10, 1994 8:00 AM UTC
Gilead Sciences Inc. (GILD), Foster City, Calif. Product: GS 504, small-molecule nucleotide analog Indication: Treatment of peripheral retinitis due to cytomegalovirus (CMV) in AIDS patients. The tri...